Anti-CD19 FasT CAR-T cell therapy (Gracell Biotechnologies (Shanghai) Co Ltd)

N/A

Report date: 2024/12/20 10:28:09

Base Information

Drug NameAnti-CD19 FasT CAR-T cell therapy (Gracell Biotechnologies (Shanghai) Co Ltd)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesGracell Biotechnologies (Shanghai) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGracell Biotechnologies (Shanghai) Co Ltd

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A